Percutaneous radiofrequency ablation for unresectable large hepatic tumours during hepatic blood flow occlusion in four patients

[Guest guest]

Clinical Radiology

Volume 59, Issue 9 , September 2004, Pages 812-818

doi:10.1016/j.crad.2004.03.004

Copyright © 2004 The Royal College of Radiologists. Published by Elsevier

Ltd.

Percutaneous radiofrequency ablation for unresectable large hepatic tumours

during hepatic blood flow occlusion in four patients

N. Miyamoto, , a, K. Tsujib, Y. Sakuraia, H. Nishimorib, J. -H. Kangb, S.

Mitsuib and H. Maguchib

a Department of Radiology, Teine Keijinkai Hospital, Sapporo, Japan

b Department of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan

Received 28 September 2003; Revised 26 February 2004; accepted 2 March

2004. Available online 9 September 2004.

Abstract

AIM: To evaluate percutaneous radiofrequency (RF) ablation therapy for

unresectable large hepatic tumours combined with regional interruption of

hepatic blood flow, and to assess the safety and efficacy of this procedure.

MATERIALS AND METHODS: Four patients with hepatic tumours were enrolled in

this study. Patients were treated by a single session of RF ablation during

occlusion of both hepatic artery and hepatic vein. Tumour size ranged from

45-57 mm (mean 50.2 mm). Initial therapeutic efficacy was evaluated with

helical computed tomography (CT) performed within 9 days after the

treatment. CT or magnetic resonance imaging (MRI) was performed every 2-3

months thereafter.

RESULTS: The largest axis of coagulated lesions after the ablation was 50-60

mm (mean 56.5 mm) in diameter. The ablation therapy was considered complete

in three patients; after a mean follow-up of 12.7 months, CT and MRI

revealed complete destruction of their tumours. One patient required further

treatment. No severe complications occurred.

CONCLUSION: Although further studies are needed, in this limited clinical

trial a local ablation area exceeding 50 mm in diameter was achieved safely.

FULL TEXT

ARTICLEL:http://www.sciencedirect.com/science?_ob=ArticleURL & _udi=B6WCP-4D8VC31-\

7 & _user=10 & _handle=B-WA-A-W-BU-MsSAYWW-UUW-AUEEWUVBVV-AUEZDYCAVV-ZCBUUADEA-BU-U & \

_fmt=full & _coverDate=09%2F30%2F2004 & _rdoc=6 & _orig=browse & _srch=%23toc%236744%232\

004%23999409990%23519091! & _cdi=6744 & view=c & _acct=C000050221 & _version=1 & _urlVersi\

on=0 & _userid=10 & md5=f2206f537f1b31704eb3a1f093d0f0c0

[Guest guest]

Clinical Radiology

Volume 59, Issue 9 , September 2004, Pages 812-818

doi:10.1016/j.crad.2004.03.004

Copyright © 2004 The Royal College of Radiologists. Published by Elsevier

Ltd.

Percutaneous radiofrequency ablation for unresectable large hepatic tumours

during hepatic blood flow occlusion in four patients

N. Miyamoto, , a, K. Tsujib, Y. Sakuraia, H. Nishimorib, J. -H. Kangb, S.

Mitsuib and H. Maguchib

a Department of Radiology, Teine Keijinkai Hospital, Sapporo, Japan

b Department of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan

Received 28 September 2003; Revised 26 February 2004; accepted 2 March

2004. Available online 9 September 2004.

Abstract

AIM: To evaluate percutaneous radiofrequency (RF) ablation therapy for

unresectable large hepatic tumours combined with regional interruption of

hepatic blood flow, and to assess the safety and efficacy of this procedure.

MATERIALS AND METHODS: Four patients with hepatic tumours were enrolled in

this study. Patients were treated by a single session of RF ablation during

occlusion of both hepatic artery and hepatic vein. Tumour size ranged from

45-57 mm (mean 50.2 mm). Initial therapeutic efficacy was evaluated with

helical computed tomography (CT) performed within 9 days after the

treatment. CT or magnetic resonance imaging (MRI) was performed every 2-3

months thereafter.

RESULTS: The largest axis of coagulated lesions after the ablation was 50-60

mm (mean 56.5 mm) in diameter. The ablation therapy was considered complete

in three patients; after a mean follow-up of 12.7 months, CT and MRI

revealed complete destruction of their tumours. One patient required further

treatment. No severe complications occurred.

CONCLUSION: Although further studies are needed, in this limited clinical

trial a local ablation area exceeding 50 mm in diameter was achieved safely.

FULL TEXT

ARTICLEL:http://www.sciencedirect.com/science?_ob=ArticleURL & _udi=B6WCP-4D8VC31-\

7 & _user=10 & _handle=B-WA-A-W-BU-MsSAYWW-UUW-AUEEWUVBVV-AUEZDYCAVV-ZCBUUADEA-BU-U & \

_fmt=full & _coverDate=09%2F30%2F2004 & _rdoc=6 & _orig=browse & _srch=%23toc%236744%232\

004%23999409990%23519091! & _cdi=6744 & view=c & _acct=C000050221 & _version=1 & _urlVersi\

on=0 & _userid=10 & md5=f2206f537f1b31704eb3a1f093d0f0c0

[Guest guest]

Clinical Radiology

Volume 59, Issue 9 , September 2004, Pages 812-818

doi:10.1016/j.crad.2004.03.004

Copyright © 2004 The Royal College of Radiologists. Published by Elsevier

Ltd.

Percutaneous radiofrequency ablation for unresectable large hepatic tumours

during hepatic blood flow occlusion in four patients

N. Miyamoto, , a, K. Tsujib, Y. Sakuraia, H. Nishimorib, J. -H. Kangb, S.

Mitsuib and H. Maguchib

a Department of Radiology, Teine Keijinkai Hospital, Sapporo, Japan

b Department of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan

Received 28 September 2003; Revised 26 February 2004; accepted 2 March

2004. Available online 9 September 2004.

Abstract

AIM: To evaluate percutaneous radiofrequency (RF) ablation therapy for

unresectable large hepatic tumours combined with regional interruption of

hepatic blood flow, and to assess the safety and efficacy of this procedure.

MATERIALS AND METHODS: Four patients with hepatic tumours were enrolled in

this study. Patients were treated by a single session of RF ablation during

occlusion of both hepatic artery and hepatic vein. Tumour size ranged from

45-57 mm (mean 50.2 mm). Initial therapeutic efficacy was evaluated with

helical computed tomography (CT) performed within 9 days after the

treatment. CT or magnetic resonance imaging (MRI) was performed every 2-3

months thereafter.

RESULTS: The largest axis of coagulated lesions after the ablation was 50-60

mm (mean 56.5 mm) in diameter. The ablation therapy was considered complete

in three patients; after a mean follow-up of 12.7 months, CT and MRI

revealed complete destruction of their tumours. One patient required further

treatment. No severe complications occurred.

CONCLUSION: Although further studies are needed, in this limited clinical

trial a local ablation area exceeding 50 mm in diameter was achieved safely.

FULL TEXT

ARTICLEL:http://www.sciencedirect.com/science?_ob=ArticleURL & _udi=B6WCP-4D8VC31-\

7 & _user=10 & _handle=B-WA-A-W-BU-MsSAYWW-UUW-AUEEWUVBVV-AUEZDYCAVV-ZCBUUADEA-BU-U & \

_fmt=full & _coverDate=09%2F30%2F2004 & _rdoc=6 & _orig=browse & _srch=%23toc%236744%232\

004%23999409990%23519091! & _cdi=6744 & view=c & _acct=C000050221 & _version=1 & _urlVersi\

on=0 & _userid=10 & md5=f2206f537f1b31704eb3a1f093d0f0c0

[Guest guest]

Clinical Radiology

Volume 59, Issue 9 , September 2004, Pages 812-818

doi:10.1016/j.crad.2004.03.004

Copyright © 2004 The Royal College of Radiologists. Published by Elsevier

Ltd.

Percutaneous radiofrequency ablation for unresectable large hepatic tumours

during hepatic blood flow occlusion in four patients

N. Miyamoto, , a, K. Tsujib, Y. Sakuraia, H. Nishimorib, J. -H. Kangb, S.

Mitsuib and H. Maguchib

a Department of Radiology, Teine Keijinkai Hospital, Sapporo, Japan

b Department of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan

Received 28 September 2003; Revised 26 February 2004; accepted 2 March

2004. Available online 9 September 2004.

Abstract

AIM: To evaluate percutaneous radiofrequency (RF) ablation therapy for

unresectable large hepatic tumours combined with regional interruption of

hepatic blood flow, and to assess the safety and efficacy of this procedure.

MATERIALS AND METHODS: Four patients with hepatic tumours were enrolled in

this study. Patients were treated by a single session of RF ablation during

occlusion of both hepatic artery and hepatic vein. Tumour size ranged from

45-57 mm (mean 50.2 mm). Initial therapeutic efficacy was evaluated with

helical computed tomography (CT) performed within 9 days after the

treatment. CT or magnetic resonance imaging (MRI) was performed every 2-3

months thereafter.

RESULTS: The largest axis of coagulated lesions after the ablation was 50-60

mm (mean 56.5 mm) in diameter. The ablation therapy was considered complete

in three patients; after a mean follow-up of 12.7 months, CT and MRI

revealed complete destruction of their tumours. One patient required further

treatment. No severe complications occurred.

CONCLUSION: Although further studies are needed, in this limited clinical

trial a local ablation area exceeding 50 mm in diameter was achieved safely.

FULL TEXT

ARTICLEL:http://www.sciencedirect.com/science?_ob=ArticleURL & _udi=B6WCP-4D8VC31-\

7 & _user=10 & _handle=B-WA-A-W-BU-MsSAYWW-UUW-AUEEWUVBVV-AUEZDYCAVV-ZCBUUADEA-BU-U & \

_fmt=full & _coverDate=09%2F30%2F2004 & _rdoc=6 & _orig=browse & _srch=%23toc%236744%232\

004%23999409990%23519091! & _cdi=6744 & view=c & _acct=C000050221 & _version=1 & _urlVersi\

on=0 & _userid=10 & md5=f2206f537f1b31704eb3a1f093d0f0c0